Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

CURE-SHOCK Cure-shock: Procizumab to Reduce Morbidity and Mortality in Circulatory Shock

Coordinator
Universitaetsklinikum Hamburg-Eppendorf, Germany
Runs
1 June 2026 to 30 November 2029
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
6 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101290723

What the project is doing

In the project's own words, from its summary on CORDIS.

Circulatory shock, encompassing septic, burn, and traumatic shock, affects over 500,000 patients annually in the EU and USA. It represents a life-threatening condition with 30–50% mortality within 30 days of hospitalization. Current treatments are limited to supportive care, lacking causal therapies. The CURE-SHOCK project, led by UKE Hamburg/ Germany in collaboration with UKSH Lübeck/ Germany, CLO/ Poland, and BNMU/ Ukraine, and the German SME 4TEEN4 Pharmaceuticals, addresses this gap by targeting Dipeptidyl Peptidase 3 (DPP3).

DPP3 is a key driver of hemodynamic instability in circulatory shock. Procizumab, a novel monoclonal anti-DPP3 antibody, neutralizes DPP3, thereby restoring blood pressure homeostasis and stabilizing circulation. Preclinical studies and compassionate use cases demonstrate promising efficacy, with completed Phase 1 study confirming tolerability. CURE-SHOCK aims to conduct a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial with 150 patients (50 each for septic, burn, and traumatic shock) to provide the first efficacy and safety evidence of Procizumab in these shock entities.

The trial will leverage four expert sites, using a personalized approach with DPP3 point-of-care testing. Aligned with HORIZON-HLTH-2025-01-TOOL-05, CURE-SHOCK advances biotech translation into innovative therapies, addressing unmet needs in critical care. It strengthens EU biotech competitiveness, fosters cross-border collaboration, and supports precision medicine, and holds the potential of saving tens of thousands lives annually.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyCoordinator
4TEEN4 Pharmaceuticals GmbHHennigsdorfGermanyParticipant
Universitaet Zu LuebeckLubeckGermanyThird party
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Centrum Leczenia Oparzen Im. Dr.stanislawa Sakiela W Siemianowicach SlaskichSiemianowice SlaskiePolandParticipant
Bogomolets National Medical UniversityKyivUkraineParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI